Joseph Truluck - 23 May 2023 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Chief Financial Officer
Issuer ticker: ADIL
Reported as of: 23 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 May 2023, 16:50:18 UTC
Prior SEC filing: 25 Feb 2022
Next SEC filing: 27 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Joseph Truluck

Key filing fact

Joseph Truluck filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 25 May 2023.

Key facts

This page summarizes Joseph Truluck's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 May 2023, 16:50.

Change

Previous filing in this sequence was filed on 25 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADIL transaction

Common Stock

Award

Transaction value: $0
Shares: +157,500
Change %: +146%
Price: $0.000000
Shares after: 265,139
Date: 23 May 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 23 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.3025
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .